With this new manufacturing platform, SIMABS will target two market segments:
- Companies that produce therapeutic biosimilars at a smaller scale in a cost-efficient way.
- Small clinical batches for innovative biopharmaceutical companies that want to outsource their GMP production.
SIMABS will provide services with regards to project management and technology transfer for the manufacturing of monoclonal antibodies to these companies.
